Alluvi Glow GHK-Cu 70mg Pen Kit (2 x 35mg Pens)

Description

Alluvi Glow GHK-Cu is a research-grade tri-peptide formulation combining three distinct peptides — GHK-Cu (50mg), BPC-157 (10mg), and TB-500 (10mg) — in a single 70mg pre-filled kit. Each kit contains two multi-dose research pens, formulated in a sterile liquid buffer. The formulation is investigated for its complementary actions on gene transcription, vascular formation, and cellular motility.

Alluvi Healthcare provides this compound in precisely measured, independently verified formats designed for structured laboratory assessment.

The Tri-Pathway Mechanism

The three peptides in the Glow matrix target distinct but interconnected areas of cellular biology:

GHK-Cu — Gene Transcription and Extracellular Matrix

GHK (glycyl-L-histidyl-L-lysine) is a human plasma tripeptide with high copper affinity, first isolated by Dr Loren Pickart in 1973. Published literature documents that endogenous human plasma GHK concentrations decline with age, from roughly 200 ng/mL at age 20 to approximately 80 ng/mL by age 60. In cellular and genomic models, GHK-Cu modulates more than 4,000 human genes. Researchers observe that it regulates matrix metalloproteinases (MMPs) alongside tissue inhibitors of metalloproteinases, stimulating mRNA expression for Type I and Type III collagen, elastin, and decorin. In murine and in-vitro hair models, GHK-Cu is studied for its ability to enlarge follicle diameter and prolong the anagen growth phase, while downregulating inflammatory signalling via NF-κB pathways.

BPC-157 — Angiogenesis and Micro-Vascularisation

Body Protection Compound-157 is a 15-amino acid peptide derived from gastric juice proteins. In animal and tissue models, it is investigated primarily for its angiogenic action. Published research reports that BPC-157 upregulates Vascular Endothelial Growth Factor (VEGF) and activates early growth response-1 (egr-1), accelerating the formation of capillary networks that deliver oxygen and nutrients to damaged connective and soft tissue structures.

TB-500 — Cytoskeletal Actin and Cellular Motility

TB-500 is a synthetic fraction of Thymosin Beta-4, an endogenous 43-amino acid peptide. Its primary biological function in research literature is actin regulation. By sequestering and upregulating G-actin, TB-500 supports rapid cell migration. In tissue studies, this allows fibroblasts, keratinocytes, and endothelial cells to move fluidly across the extracellular matrix to sites of inflammation and mechanical disruption.

Note: These are pharmacological observations from published in-vitro and animal research models. They are not therapeutic outcomes, and this product is not supplied for human administration.

Product Specifications

Storage and Handling

Multi-peptide formulations are structurally sensitive. Laboratory handling conditions determine whether the material maintains the purity documented on the Certificate of Analysis.

• Refrigerate at 2°C to 8°C immediately on receipt. Protect from direct light. Never freeze liquid peptide pens — ice crystal formation permanently shears peptide bonds.
• Pre-filled liquid integrity. Unlike lyophilised vials requiring manual reconstitution with bacteriostatic water, Alluvi pre-filled pens are factory-formulated in a sterile buffer, eliminating needle-shearing risks and dilution errors.
• Check on arrival: confirm packaging and tamper seals are intact, match batch number GL0621XSA to the outer carton. Note that slight optical opalescence of the liquid is normal at this peptide concentration. Refrigerate immediately. Report any transit damage or temperature excursions within 48 hours.
• Trace metal considerations. GHK-Cu carries a bound copper(II) ion. In biochemical investigations, free copper interacts with reducing agents such as ascorbic acid (Vitamin C), leading to mutual oxidation. Research protocols should account for mineral interactions when designing testing matrices.
• Purity is not sterility. An analytical purity score of 99.4% verifies chemical identity and the absence of peptide fragments. It does not certify sterility for human consumption or medical administration.

The Alluvi Healthcare Standard

• Independent Third-Party Testing. HPLC and mass spectrometry on every lot by Janoshik Analytical. Public task numbers checkable directly on the lab portal.
• Multi-Peptide Assay Precision. The Certificate of Analysis reports individual concentrations for GHK-Cu, BPC-157, and TB-500, proving each component is present at target ratios.
• Cold-Chain Integrity. Insulated dispatch packaging with temperature-control cooling packs ensures peptide stability during transit.
• Batch-Specific Traceability. Outer cartons and pen bodies carry matching lot numbers tied directly to analytical certificates.
• Fixed-Volume Liquid Devices. Sealed multi-chamber pens prevent contamination and eliminate concentration variance from manual reconstitution.

Important Research Disclaimer

Strictly for Laboratory and Scientific Research Use Only.

Alluvi Glow GHK-Cu is not intended for human consumption, veterinary use, self-administration, clinical use, treatment, diagnosis, prevention, cosmetic use, supplement use, or any form of personal use. Components including BPC-157 and TB-500 are experimental and lack comprehensive human clinical trials. They are not approved medicines for cosmetic or systemic use.

We do not provide dosing guidance, preparation instructions, administration guidance, or personal-use support. Customers must ensure all products are handled responsibly within appropriate laboratory environments.

GLOW vs KLOW: Formulation Comparison